Method and composition for treating prostate cancer
A method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase. In one embodiment, a method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase and at least one of a glycosidase, a protease, a nuclease, a lipase, an esterase, a plasminogen activator, a streptokinase, and combinations thereof. Preferably a glycosidase, such as, for example, hyaluronidase, is administered. Compositions used in methods for treating prostate cancer can also include or be administered with calcium ions, a nonionic surfactant, such as, for example, Triton® X-100, and an antibiotic, such as, for example, gentamicin. Another method of treating prostate cancer in a living mammal includes activating PSA in vivo by, for example, locally administering calcium ions.
1. A method of degrading a prostate tumor in a mammal comprising local administration to the prostate of a composition comprising therapeutically effective concentrations of collagenase, hyaluronidase, and calcium ions.
2. The method of claim 1 , wherein the composition comprises about 1 mM to about 50 mM calcium ions.
3. The method of claim 1 , wherein the calcium ions comprise a calcium salt.
4. The method of claim 3 , wherein the calcium salt comprises calcium chloride.
5. The method of claim 1 , wherein the composition comprises about 1 mM to about 50 mM calcium ions, about 250 to about 250,000 U/ml collagenase and about 160 to about 160,000 U/ml hyaluronidase.
6. The method of claim 1 , wherein the composition further comprises an effective concentration of a nonionic surfactant.
7. The method of claim 6 , wherein the nonionic surfactant comprises octylphenoxypolyethoxyethanol.
8. The method of claim 1 , wherein the composition further comprises an effective concentration of an antibiotic.
9. The method of claim 8 , wherein the antibiotic comprises gentamicin sulfate.
10. The method of claim 1 , wherein local administration comprises intraprostatic injection.
11. The method of claim 10 , wherein intraprostatic injection comprises intralesional injection, transurethral injection, transrectal injection, or transperineal injection.
12. The method of claim 10 , comprising administering a single injection of about 1 to 50 ml.
13. The method of claim 10 , comprising administering a single injection of about 1 to 5 ml.
14. The method of claim 1 , wherein local administration comprises administering a depot formulation.
15. The method of claim 1 , wherein local administration comprises administering a slow release implant, a microencapsulated composition, a conjugate with a biodegradable polymer, or a conjugate with a prostate-specific immunoglobulin.
16. A method of degrading a prostate tumor in a mammal comprising local administration to the prostate of a sterile pyrogen-free solution comprising effective concentrations of calcium ions, collagenase, hyaluronidase, a nonionic surfactant, an antibiotic, and a pharmaceutically acceptable aqueous carrier having a physiologic pH; wherein the solution is suitable for administration to living mammals at single or multiple dosages of about 1 to 50 ml via intraprostatic injection; and wherein administration of said solution causes the necrosis, liquification, and regression of said tumor.
17. The method of claim 16 , wherein collagenase is provided at a concentration of about 2,500 to 25,000 U/ml.
18. The method of claim 16 , wherein hyaluronidase is provided at a concentration of about 1,600 to 16,000 U/ml.
19. The method of claim 16 , wherein the nonionic surfactant comprises octylphenoxypolyethoxyethanol.
20. The method of claim 16 , wherein the antibiotic comprises gentamicin.
21. The method of claim 16 , wherein the intraprostatic injection comprises intralesional injection, transurethral injection, transrectal injection, or transperineal injection.
22. The method of claim 16 , comprising administering a single injection of about 1 to 20 ml.